Immunogenicity of a BNT162b2 vaccine booster in health-care workers

Immunogenicity of a BNT162b2 vaccine booster in health-care workers

Bibliographic Details
Main Authors:	Esther Saiag, Hanoch Goldshmidt, Eli Sprecher, Ronen Ben-Ami, David Bomze
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	The Lancet Microbe
Online Access:	http://www.sciencedirect.com/science/article/pii/S266652472100272X

Similar Items

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
by: Sabina Zurac, et al.
Published: (2022-07-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
by: Laura Gianserra, et al.
Published: (2022-08-01)

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
by: Jitka Smetanova, et al.
Published: (2022-09-01)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
by: Yael Shachor-Meyouhas, et al.
Published: (2023-01-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
by: Toshinori Nishizawa, et al.
Published: (2022-09-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
by: Thanyawee Puthanakit, et al.
Published: (2022-09-01)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
by: Tomer Hertz, et al.
Published: (2023-07-01)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
by: Rui Li, et al.
Published: (2022-06-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
by: Louise Murdoch, et al.
Published: (2023-09-01)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Payne, RP, et al.
Published: (2021)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
by: Diletta Valentini, et al.
Published: (2022-01-01)

Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
by: Mohammad Shehab, et al.
Published: (2022-07-01)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
by: Daniela Dalla Gasperina, et al.
Published: (2023-09-01)

The Persistence of Antibodies in ESRD Patients 12 Months after the BNT162b2 Vaccine Booster Dose.
by: Ummu Afeera, Zainulabid, et al.
Published: (2024)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
by: Porntip Intapiboon, et al.
Published: (2021-11-01)

Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients
by: Ahmed Amine Ben Khlil, et al.
Published: (2024-02-01)

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
by: Simon Dedroogh, et al.
Published: (2023-06-01)

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
by: Hiroyuki Naruse, et al.
Published: (2021-11-01)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
by: Theodoros Karampitsakos, et al.
Published: (2022-05-01)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
by: Khetam Hussein, et al.
Published: (2022-10-01)

Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
by: Line Dam Heftdal, et al.
Published: (2023-12-01)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccineResearch in context
by: Lorenzo Azzi, et al.
Published: (2023-02-01)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
by: Ofra Amir, et al.
Published: (2022-04-01)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
by: Natalia Vargas-Herrera, et al.
Published: (2022-01-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
by: Michal Herman-Edelstein, et al.
Published: (2022-06-01)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024-02-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
by: Aharona Glatman-Freedman, et al.
Published: (2022-05-01)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
by: Merav Mofaz, et al.
Published: (2022-07-01)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
by: Metin Yigit, et al.
Published: (2022-08-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
by: Osnat Itzhaki Ben Zadok, et al.
Published: (2022-04-01)